Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Symphogen logo — company profile

Symphogen

Founded 2000 Denmark Denmark 188 employees Debt Financing Total: $314.00M Biopharma, Biotechnology +1

General Information

Company Name Symphogen
Founded Year 2000
Location Denmark Denmark +2
Employees 188
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Debt Financing
Social

Get notified when Symphogen moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Symphogen

Symphogen:

Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers.

Founded in 2000 and headquartered in Denmark, Symphogen operates in the Biopharma, Biotechnology, Pharmaceutical industries. The company received a €67.50M Debt Financing investment on 22 October 2015 from Novo Holdings and PKA.

Taxonomy: biologics development, antibodies, oncology, immune-oncology, R&D strategy, clinical stages, compounds, therapies, cancer treatment, drug development

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing •••••• 2
Investor Investor
22 Oct 2015
Private Equity Round •••••• 3
Investor Investor
•••• •••• 		03 May 2013
Venture Round •••••• 3
Investor Investor
•••• •••• 		06 Jan 2011
Venture Round •••••• 1 •••• •••• 02 Feb 2009
Private Equity Round •••••• 1 •••• •••• 10 Jun 2008

View All 10 Funding Rounds

Symphogen Alternatives & Competitors

Symphogen vs
ImmuneOncia Therapeutics Inc.
ImmuneOncia Therapeutics Inc. Korea South

Changing the Standard of cancer treatment by bringing Korea's 1st immuno-oncology drug

Series Unknown
18 employees
Biotechnology, Pharmaceutical
Compare Symphogen vs ImmuneOncia Therapeutics Inc.
Symphogen vs
Mabqi
Mabqi France

Your key partner for breakthrough antibody discovery

26 employees
Biotechnology
Compare Symphogen vs Mabqi
Symphogen vs
Kanova
Kanova

Pioneering advanced therapies in immuno-oncology and autoimmune diseases.

Series B
2-10 employees
Biopharma, Health and Wellness
Compare Symphogen vs Kanova

FAQ About Symphogen

Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology...
Symphogen was founded in 2000.
Symphogen is headquartered in Denmark.
Symphogen operates in the following industries: Biopharma, Biotechnology, Pharmaceutical.
Symphogen has approximately 188 employees.
Symphogen has completed 10 funding rounds, raising a total of $314.00M. The latest funding stage is Debt Financing.
Top alternatives and competitors to Symphogen include ImmuneOncia Therapeutics Inc., Mabqi, Kanova, DotBio, EpimAb Biotherapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Symphogen and ImmuneOncia Therapeutics Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Symphogen and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy